Navigation Links
NovoBioPharma, Partnership of Top Life Science Experts, Launches
Date:6/11/2013

CAMBRIDGE, Mass., June 11, 2013 /PRNewswire/ -- NovoBioPharma, a partnership of experts collaborating with life science organizations to provide comprehensive medical, scientific, regulatory, business and financial advisory services, launched today. The global business is comprised of four principals, all experts in their fields, who partnered to create an entity to help life science companies and institutions to cost-efficiently advance drug, diagnostic and device candidates by leveraging opportunities from conception through clinical development, and ultimately, regulatory approval.

With decades of experience and a global network in all areas of business, finance, drug, diagnostic and device development, NovoBioPharma offers services in capital sourcing and management, business development, intellectual property, quality control, manufacturing, study design, and protocol development. Simply put, NovoBioPharma covers every facet of the risky and costly work of developing life science breakthroughs.

The NovoBioPharma team is:

Bernie Rudnick, MBA, Chief Business Officer, is founder and managing partner of CapGenic Advisors, LLC, and a founding member of several Angel investing groups. Mr. Rudnick has substantial experience investing and guiding investments in entrepreneurial companies; he has led capital formation totaling more than $530 million in the past ten years and $3B during the last 15 years. Mr. Rudnick, a serial entrepreneur, founded, managed and advised numerous companies in the life sciences, including diagnostic, therapeutic and clinical software environments.  Mr. Rudnick is experienced in forms of capital formation including angel networks, venture capital funds, SBIR and other government grant programs. He is a graduate of Penn State and Northwood University.

Ira Wallace, MD, MBA is Chief Development Officer for NovoBioPharma. Dr. Wallace has been involved in pharmaceutical, biotech and medical device companies as a CEO, founder, board member and consultant.  In addition, Dr. Wallace is experienced in technology transfer and intellectual property strategies and is a founding member and partner in a number of Angel investment groups. A graduate of the University of Pennsylvania, Dr. Wallace earned his medical degree at Drexel Medical School and his MBA at Columbia.

Shahin Gharakhanian MD, Head, Pharmaceutical Medicine, is an infectious diseases and internal medicine trained physician with over 20 years experience in the pharmaceutical industry and clinical practice. His last position was Vice President in the Medicines Development Group/Global R&D at Vertex Pharmaceuticals, Inc. Cambridge MA, USA. In industry, Dr. Gharakhanian has driven: strategic leadership, clinical development and medical affairs. Overall, he has handled projects for twelve different pharmaceutical companies, ten different brands and four drug launches in Asia, Canada, EU and the United States. His most recent major New Drug Application/launch experience was in 2011. Dr. Gharakhanian earned his specialty medical degrees at University of Paris, and trained/practiced in AP-HP, Paris, France, the largest hospital system in Europe and one of the largest in the world.

Andrew D. Luber, PharmD Chief Scientific Officer, is an infectious diseases trained clinical pharmacist/pharmacologist with over 18 years experience working with the pharmaceutical industry as an investigator, key opinion leader, speakers bureau, steering committee and advisory board member.  In addition, he has served as a clinical consultant to large and early stage pharmaceutical companies.  Dr. Luber has been an investigator in more than 70 clinical trials including four Phase 1a first in human studies and specializes in early stage drug development. Dr. Luber received his doctor of pharmacy at Temple University and did his post-doctoral residencies and research fellowship at the University of California, San Francisco Medical Center and School of Pharmacy.

For more information, visit the website at NovoBioPharma
Contact:  Andrew D. Luber, PharmD 1-856-258-0850


'/>"/>
SOURCE NovoBioPharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis and Medicines360 Announce Partnership to Advance Womens Access to Affordable IUDs
2. Elekta-Equra Health Partnership to Increase South African Cancer Patients Access to Radiation Therapy
3. AmeriCares Honors Merck with Power of Partnership Award
4. PDR Network and OPTIMIZERx (SampleMD) Announce Partnership to Deliver Patient Financial Support Programs Within EHR Workflow
5. Mylan Specialty L.P. Announces Partnership with Baseball Teams Across Country to Raise Awareness of Potentially Life-Threatening Allergies
6. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
7. Life Line Screening and MCM Solutions for Better Health Announce New Partnership
8. United Way and FamilyWize Partnership Has Helped 5 Million People Stay Healthy
9. Allergans Global Dominance in Facial Injectables Challenged by Acquisitions and Partnership Agreements Among Competitors
10. Partnership Formed to Explore Personalized Medicine Approach for Amyotrophic Lateral Sclerosis (ALS) Treatments
11. Huahai and Oncobiologics Create Broad Biosimilars Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 Report Details ... ... for Leading Companies – our new study reveals trends, ... issues and events affecting the Alzheimer,s disease therapeutics and ... answer these key questions: - How is the Alzheimer,s ...
(Date:1/19/2017)... 19, 2017 Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase ... The global anti-obesity drugs market is expected to ... the forecast period and CAGR of 38.7% in the second half ... a CAGR of 32.8% from 2016 to 2027. The market is ... $24,063 million in 2027. ...
(Date:1/19/2017)... , January 19, 2017 ... ; European Oncology & Haematology, 2016;12(Suppl 2):3-8; ... ... Published recently in a ... peer-reviewed journal from touchONCOLOGY, an article by ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... 20, 2017 , ... “The Land of More and More”: a brilliant ... hunger, and shares the simple and achievable answer. “The Land of More and More” ... Fairview Missionary Church in Angola, Indiana where he works with the children’s ministry department. ...
(Date:1/19/2017)... ... January 20, 2017 , ... Today, the Centers for Medicare & Medicaid Services ... Alternative Payment Models (APMs) in 2017. Clinicians who participate in APMs are paid for ... part of the Administration’s effort to build a system that delivers better care and ...
(Date:1/19/2017)... ... January 19, 2017 , ... Next week after January 20th, the ... Congressional political games that circumvent health needs of over 30 million. Many interviews with ... anxieties and needs government public servants were suppose to prioritize. Interviews provided below. ...
(Date:1/19/2017)... ... January 19, 2017 , ... With the cold weather here, many people will have ... are efficient when clearing large amounts of snow, but they can be dangerous when used ... Consumer Product Safety Commission for the proper use of snow blowers:, , ...
(Date:1/19/2017)... ... January 19, 2017 , ... LabRoots ... scientists from around the world, announces the launch of its newly redesigned website. ... portal to research breakthroughs and trending news, vital information on upcoming virtual events ...
Breaking Medicine News(10 mins):